# Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

> **NCT06462105** · NA · NOT_YET_RECRUITING · sponsor: **Zhou Chengzhi** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection

## Key facts

- **NCT ID:** NCT06462105
- **Lead sponsor:** Zhou Chengzhi
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-05
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-06-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462105, "Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06462105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*